Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/09/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/02/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/24/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 04/03/2023 | 83.69% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 11/08/2022 | 32.26% | Goldman Sachs | $13 → $18 | Maintains | Neutral |
| 08/16/2022 | -4.48% | Goldman Sachs | $10 → $13 | Maintains | Neutral |
| 05/24/2022 | -26.52% | Goldman Sachs | $22 → $10 | Maintains | Neutral |
| 11/24/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/23/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/23/2021 | 113.08% | Goldman Sachs | → $29 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/22/2023 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 购买→购买 |
| 08/09/2023 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 购买→购买 |
| 08/02/2023 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 购买→购买 |
| 2023年05月24日 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 购买→购买 |
| 04/03/2023 | 83.69% | HC Wainwright公司 | →$25 | 开始承保 | →购买 |
| 11/08/2022 | 32.26% | 高盛 | $13→$18 | 维护 | 中性 |
| 08/16/2022 | -4.48% | 高盛 | $10→$13 | 维护 | 中性 |
| 2022年05月24日 | -26.52% | 高盛 | $22→$10 | 维护 | 中性 |
| 2021年11月24日 | - | Evercore ISI集团 | 开始承保 | →跑赢大盘 | |
| 2021年11月23日 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 2021年11月23日 | 113.08% | 高盛 | →$29 | 开始承保 | →中性 |
What is the target price for Entrada Therapeutics (TRDA)?
Entrada治疗公司(TRDA)的目标价格是多少？
The latest price target for Entrada Therapeutics (NASDAQ: TRDA) was reported by HC Wainwright & Co. on September 22, 2023. The analyst firm set a price target for $25.00 expecting TRDA to rise to within 12 months (a possible 83.69% upside). 6 analyst firms have reported ratings in the last year.
恩特拉达治疗公司(纳斯达克代码：TRDA)的最新目标价是由HC Wainwright&Co.于2023年9月22日报道的。这家分析公司将目标价定为25.00美元，预计TRDA将在12个月内升至(可能上涨83.69%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
Entrada治疗公司(TRDA)的最新分析师评级是多少？
The latest analyst rating for Entrada Therapeutics (NASDAQ: TRDA) was provided by HC Wainwright & Co., and Entrada Therapeutics reiterated their buy rating.
恩特拉达治疗公司(纳斯达克代码：TRDA)的最新分析师评级由HC Wainwright&Co.提供，恩特拉达治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Entrada治疗公司(TRDA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Entrada治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Entrada治疗公司的上一次评级是在2023年9月22日提交的，因此您应该预计下一次评级将在2024年9月22日左右提供。
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
分析师对Entrada Treeutics(TRDA)的评级正确吗？
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a reiterated with a price target of $0.00 to $25.00. The current price Entrada Therapeutics (TRDA) is trading at is $13.61, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Entrada治疗公司(TRDA)评级被重申，目标价在0.00美元至25.00美元之间。Entrada治疗公司(TRDA)目前的交易价格为13.61美元，在分析师的预测范围内。